S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Biden’s $374B Giveaway Into This Sector (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The A.I. story nobody is telling you (Read ASAP) (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Biden’s $374B Giveaway Into This Sector (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The A.I. story nobody is telling you (Read ASAP) (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Biden’s $374B Giveaway Into This Sector (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The A.I. story nobody is telling you (Read ASAP) (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
Biden’s $374B Giveaway Into This Sector (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The A.I. story nobody is telling you (Read ASAP) (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:DFFN

Diffusion Pharmaceuticals (DFFN) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)
Free DFFN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$4.38
▼
$6.60
52-Week Range
N/A
Volume
351,000 shs
Average Volume
10,937 shs
Market Capitalization
$8.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
DFFN stock logo

About Diffusion Pharmaceuticals Stock (NASDAQ:DFFN)

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

DFFN Stock News Headlines

April 18, 2024 | bbc.co.uk
Comparing diffusion, osmosis and active transport
February 10, 2024 | thestreet.com
Diffusion Pharmaceuticals Inc.
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
February 8, 2024 | bizjournals.com
Vertex co-founder Josh Boger joins Boston biotech working on dementia drug
December 22, 2023 | venturebeat.com
Stable Video Diffusion is now available through Stability AI API
August 16, 2023 | finanznachrichten.de
Diffusion Pharmaceuticals Inc.: Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
August 16, 2023 | finanznachrichten.de
Diffusion Pharmaceuticals Inc.: Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma / Announces 1-for-1.5 Reverse Stock Split
August 15, 2023 | finance.yahoo.com
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
July 24, 2023 | finance.yahoo.com
Diffusion Pharmaceuticals Inc. (DFFN) stock forecast and price target
May 23, 2023 | benzinga.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, RADI, BGRY, DFFN
March 31, 2023 | marketwatch.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Diffusion Pharmaceuticals Inc. Merger
March 30, 2023 | technews.tmcnet.com
DFFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Diffusion Pharmaceuticals Inc. Is Fair to Shareholders
March 30, 2023 | msn.com
Diffusion to merge with EIP Pharma in all-stock deal
March 30, 2023 | finance.yahoo.com
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
December 16, 2022 | markets.businessinsider.com
Diffusion's Shareholder LifeSci Supports Company's Strategic Review Process And Director Nominees
December 16, 2022 | finance.yahoo.com
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
December 5, 2022 | finance.yahoo.com
Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing
December 1, 2022 | finance.yahoo.com
DFFN: Strategic Review Underway; Planning to Initiate Phase 2 GBM Trial in 1Q23…
November 15, 2022 | finance.yahoo.com
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022 | finance.yahoo.com
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process
October 15, 2022 | forbes.com
Diffusion Pharmaceuticals
September 29, 2022 | finance.yahoo.com
Diffusion Pharmaceuticals Inc. (DFFN)
August 17, 2022 | seekingalpha.com
Diffusion raised to Buy at H.C. Wainwright after Q2 update on lead asset
August 17, 2022 | finance.yahoo.com
DFFN: Phase 2 GBM Trial to Initiate 2H22…
August 11, 2022 | finance.yahoo.com
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
July 26, 2022 | finance.yahoo.com
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
See More Headlines
Receive DFFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DFFN
CUSIP
N/A
CIK
1053691
Web
www.diffusionpharma.com
Phone
(434) 220-0718
Fax
434-220-0722
Employees
13
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,590,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-69.96%
Return on Assets
-62.98%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.71
Quick Ratio
10.71

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.97 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,040,000
Free Float
2,003,000
Market Cap
$8.98 million
Optionable
Not Optionable
Beta
1.78
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Robert J. Cobuzzi Jr. (Age 58)
    Ph.D., Pres & CEO
    Comp: $691.79k
  • Mr. William Robert Elder J.D. (Age 40)
    Gen. Counsel & Corp. Sec.
    Comp: $413.92k
  • Dr. David Randolph Jones M.D. (Age 60)
    Sr. Medical Advisor
  • Mr. Harry Cook
    VP of Clinical Operations
  • Mr. Douglas Gravatt
    Sr. Consultant for Manufacturing
  • Mr. Brian D. Bollwage
    Sr. Consultant - Regulatory Affairs

Key Competitors

View All Competitors

DFFN Stock Analysis - Frequently Asked Questions

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($9.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.00) by $6.00.

When did Diffusion Pharmaceuticals' stock split?

Diffusion Pharmaceuticals's stock reverse split before market open on Thursday, August 17th 2023. The 1-1.5 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 67 shares after the split.

What other stocks do shareholders of Diffusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF).

This page (NASDAQ:DFFN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
How Biden has already won 2024
Porter & Company
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts